Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Charcot-Marie-Tooth Disease

View source version on businesswire.com:?https://www.businesswire.com/news/home/20190305005184/en/
Source:?Acceleron Pharma Inc. Acceleron Pharma Inc. Investors: Todd James, IRC, 617-649-9393 Vice President, Investor Relations and Corporate Communications Media: Matt Fearer, 617-301-9557 Director, Corporate Communications